We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Updated Labeling for GSK’s Zantac
FDA Approves Updated Labeling for GSK’s Zantac
February 27, 2009
The FDA approved GlaxoSmithKline’s (GSK) sNDAs for proposed changes to the “Precautions and Adverse Reactions” labeling section on three versions of its stomach ulcer drug Zantac.